Asset profile
Hemay005
Small molecule
Evidence outlook · lead readout
NCT04839328 · Psoriasis
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT04839328: The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Ulcerative Colitis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
123 competitors in this universe: 5 direct rivals (same mechanism and indication), 4 same-class, 114 same-indication; 76 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Hemay005: this drug | Phase 3 | Small molecule | PDE4 | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| HPP737 | Phase 3 | Small molecule | PDE4 | ||
| PALI-2108 | Phase 2 | Small molecule | PDE4 | ||
| PF-07038124 | Phase 2 | Small molecule | PDE4 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 | ||
| ALTO-101 | Phase 2 | Small molecule | PDE4 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha |
…and 108 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
December 2027 (1)
What to watch
2028 (1)
May 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.